Effectiveness Analysis Through Enzyme-Linked Immunosorbent Assay Examination of Antibody After Pandemic H1N1 2009 Influenza Vaccination.
10.4235/jkgs.2013.17.4.178
- Author:
Ah Young JI
1
;
Chang Oh KIM
;
Eudong HWANG
;
In Soo KIM
;
Young Ju KIM
;
Jung Hee LEE
;
Moo Nyun JIN
;
Changho SONG
;
Hye Jung PARK
;
Hyun Ju KIM
;
Sun Wook KIM
Author Information
1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. cokim@yuhs.ac
- Publication Type:Original Article
- Keywords:
H1N1 influenza;
Comorbidity;
H1N1 virus hemagglutinin;
Vaccination
- MeSH:
Aged;
Antibodies;
Cardiovascular Diseases;
Chronic Disease;
Communicable Diseases;
Comorbidity;
Diabetes Mellitus;
Enzyme-Linked Immunosorbent Assay*;
Follow-Up Studies;
Hematologic Diseases;
Humans;
Influenza A Virus, H1N1 Subtype;
Influenza, Human*;
Medical Records;
Pandemics*;
Retrospective Studies;
Tertiary Care Centers;
Vaccination*
- From:Journal of the Korean Geriatrics Society
2013;17(4):178-184
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: A pandemic influenza outbreak started in 2009 by the number of patients discharged each year. But the result of H1N1 influenza vaccination is maintained for research and less state. The purpose of this study was to measure the antibody titers after H1N1 influenza vaccination toestimate demands of different standard vaccination in patients with chronic diseases and elderly patients. METHODS: From March 2010 to February 2011, we retrospectively reviewed the medical records of 55 patients admitted to a tertiary hospital. The H1N1 virus antibody titer of each patient was measured through enzyme-linked immunosorbent assay. Titers were measured post vaccination on day 1 and at 1, 3 and 6 months. RESULTS: A total of 55 patients were enrolled in this study. The comorbidities looked at were malignancy, cardiovascular disease, diabetes mellitus, renal disease, cerebrovascular disease, hematologic disease and infectious disease. Five patients (9.1%) had no comorbidities. Patients in their 50's had the highest positive response rate (58.3%). The antibody titers at 1 month after vaccination were not associated with the number of comorbidities. The ratio of positive response increased gradually at baseline (16.4%) to 1 month (47.8%). After 6 months, there remained no positive response. CONCLUSION: The H1N1 antibodies were unstable as the values of the titer changed at follow-up (1 month, 3 months, and 6 months). The positive response rates of those in their 50's and those who had chronic diseases were higher than others. The positive response rates showed that the ability to generate antibodies did not decrease with age or disease conditions.
